Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Price Target at $63.67

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has earned an average rating of "Buy" from the seven research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $63.67.

A number of brokerages have recently commented on TARS. Barclays reduced their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Jefferies Financial Group lifted their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. HC Wainwright reissued a "buy" rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Oppenheimer raised their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Finally, Guggenheim reaffirmed a "buy" rating and issued a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th.

Insider Activity at Tarsus Pharmaceuticals

In other news, General Counsel Bryan Wahl sold 3,084 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $154,539.24. Following the completion of the sale, the general counsel now owns 51,712 shares in the company, valued at approximately $2,591,288.32. This represents a 5.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Dianne C. Whitfield sold 2,137 shares of the business's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $107,085.07. Following the transaction, the insider now owns 46,355 shares in the company, valued at approximately $2,322,849.05. This trade represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,542 shares of company stock valued at $1,581,173 over the last quarter. 8.25% of the stock is owned by corporate insiders.

Remove Ads

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Crowley Wealth Management Inc. purchased a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at about $25,000. GF Fund Management CO. LTD. purchased a new position in Tarsus Pharmaceuticals during the 4th quarter worth approximately $44,000. R Squared Ltd acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at approximately $53,000. FMR LLC boosted its holdings in shares of Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company's stock valued at $166,000 after acquiring an additional 3,537 shares during the last quarter. Finally, Quarry LP acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth $166,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Trading Up 1.0 %

TARS traded up $0.47 during trading hours on Thursday, reaching $47.49. 907,593 shares of the company's stock traded hands, compared to its average volume of 679,282. The firm has a 50-day moving average price of $49.10 and a 200 day moving average price of $46.91. The firm has a market capitalization of $1.82 billion, a PE ratio of -12.46 and a beta of 0.94. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a 52-week low of $20.08 and a 52-week high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.68) by $0.08. The firm had revenue of $66.41 million for the quarter, compared to analysts' expectations of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. As a group, sell-side analysts predict that Tarsus Pharmaceuticals will post -3.17 EPS for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.